Global Constipation Treatment Market Size (2024 - 2029)

The constipation treatment market is anticipated to experience growth driven by an increasing geriatric population, which is more susceptible to constipation due to factors such as poor diet, lack of exercise, and medication side effects. The COVID-19 pandemic has also influenced the market, as it exacerbated symptoms in individuals with pre-existing conditions like irritable bowel syndrome. Despite these growth drivers, the market's expansion may be somewhat constrained by the rising reliance on over-the-counter medications.

INSTANT ACCESS

Market Size of Global Constipation Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Constipation Treatment Market
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.90 %
Fastest Growing Market North America
Largest Market Asia Pacific
Market Concentration Low

Major Players

Global Constipation Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Constipation Treatment Market Analysis

The constipation treatment market is expected to register a CAGR of nearly 6.9% during the forecast period of 2022-2027.

The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for constipation treatment, thereby impacting the market growth. However, at the onset, SARS-CoV-2 primarily attacks the respiratory system as it represents the main point of entry in the host, but it also can affect multiple organs. According to the study "Impact of COVID-19 on individuals with Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression," published in the Journal of Clinical Gastroenterology in February 2022, individuals who have irritable bowel syndrome and comorbid anxiety and/or depression have more symptoms and a lower quality of life than those who only have Irritable bowel syndrome. As per the study findings, the current COVID-19 pandemic has the potential to exacerbate symptoms in people who have irritable bowel syndrome and also suffer from anxiety or depression. Thus, the COVID-19 outbreak and subsequent symptoms are expected to influence the global constipation treatment market during the forecast period.

The major factor attributing to the growth of the market is the increasing number of geriatric patients. These patients use analgesics such as morphine, hydromorphone, codeine, etc., as a prescription for chronic non-cancer pain, which has severe adverse effects on the digestive system resulting in huge demand for constipation drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153.3 million in 2019 and 142.8 million in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for Opioid-Induced Constipation (OIC) ailments which is likely to fuel the constipation treatment market over the forecast period.

The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases. Geriatric people are five times more prone than younger adults to experience constipation-related issues. This is caused by poor diet, a lack of sufficient fluids in the diet, a lack of exercise, the use of specific medications to treat other medical disorders, and unfavorable bowel habits are a few causes of this inclination. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. Thus, the growing geriatric population is expected to boost the target market growth over the forecast period. However, increasing dependence on the majority of over-the-counter (OTC) drugs is expected to hamper the target market to a certain extent in the studied period.

Constipation Treatment Industry Segmentation

As per the scope of the report, constipation is a common medical condition that affects the normal life of an individual, and prolonged constipation could be a symptom of more severe diseases and disorders. It is estimated to affect every individual once in a lifetime. Constipation may be occasional, which lasts for a few weeks, or maybe chronic, which lasts for a longer period and is recurrent. Therefore it may be associated with other conditions such as irritable bowel syndrome or opioid consumption also. The constipation treatment market is segmented by therapeutics (laxatives, chloride channel activators, peripherally acting Mu-opioid receptor antagonists, GC-C agonists, and others), disease type (chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC)), distribution channel (hospital, pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, and the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for the above segments.

By Therapeutics
Laxatives
Chloride Channel Activators
Peripherally Acting Mu-Opioid Receptor Antagonists
GC-C Agonists
Others
By Disease Type
Chronic idiopathic constipation (CIC)
Irritable bowel syndrome with constipation (IBS-C)
Opioid-induced constipation (OIC)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Constipation Treatment Market Size Summary

The constipation treatment market is poised for significant growth, driven by an increasing geriatric population and the rising prevalence of opioid-induced constipation. The market dynamics have been influenced by the COVID-19 pandemic, which initially reduced patient visits but later highlighted the need for effective treatments due to exacerbated symptoms in individuals with comorbid conditions like irritable bowel syndrome. The demand for constipation treatments is further fueled by the adverse effects of analgesics used by elderly patients, who are more susceptible to constipation due to factors such as poor diet, lack of exercise, and medication side effects. The growing awareness and availability of Peripherally Acting Mu-Opioid Receptor Antagonists, which have shown efficacy in treating opioid-induced constipation, are expected to contribute significantly to market expansion.

North America is anticipated to lead the global constipation treatment market, supported by a high prevalence of chronic constipation and substantial healthcare investments. The United States, in particular, holds a dominant market share due to the presence of numerous pharmaceutical companies and ongoing product launches. The market is moderately fragmented, with key players like Takeda Pharmaceutical Company Ltd., Ironwood Pharmaceuticals, and AstraZeneca Plc actively participating in the development and commercialization of new treatments. Recent regulatory approvals and product launches, such as Ardelyx, Inc.'s IBSRELA, underscore the dynamic nature of the market and its potential for continued growth over the forecast period.

Explore More

Global Constipation Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Geriatric Population and Changing Dietary Habits

      2. 1.2.2 High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation

      3. 1.2.3 Development of Latest Drugs and Treatment Procedures

    3. 1.3 Market Restraints

      1. 1.3.1 Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs

      2. 1.3.2 Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Therapeutics

      1. 2.1.1 Laxatives

      2. 2.1.2 Chloride Channel Activators

      3. 2.1.3 Peripherally Acting Mu-Opioid Receptor Antagonists

      4. 2.1.4 GC-C Agonists

      5. 2.1.5 Others

    2. 2.2 By Disease Type

      1. 2.2.1 Chronic idiopathic constipation (CIC)

      2. 2.2.2 Irritable bowel syndrome with constipation (IBS-C)

      3. 2.2.3 Opioid-induced constipation (OIC)

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Online Pharmacies

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Constipation Treatment Market Size FAQs

The Global Constipation Treatment Market is projected to register a CAGR of 6.90% during the forecast period (2024-2029)

Takeda Pharmaceutical Company Ltd, Ironwood Pharmaceuticals, Inc., AstraZeneca Plc, Salix Pharmaceuticals and Sanofi S.A. are the major companies operating in the Global Constipation Treatment Market.

Constipation Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)